Psoriatic Disease

Among patients with stable psoriatic arthritis receiving tofacitinib with methotrexate, some may be able to discontinue methotrexate without changes in disease activity or safety, according to data published in The Lancet Rheumatology.

The rate of psoriasis flares did not increase during or immediately after systemic corticosteroid treatment, according to a study published in JAMA Dermatology.

Treatment with apremilast alone is effective in patients with oligoarticular psoriatic arthritis, according to data published in The Journal of Rheumatology.

Treatment with brodalumab resulted in rapid and significant improvement in the signs and symptoms of psoriatic arthritis, compared with a placebo, according to data published in the Annals of the Rheumatic Diseases.

Greater use of effective psoriasis therapies can affect patient-reported outcomes and improve treatment satisfaction, according to a presenter at the European Academy of Dermatology and Venereology virtual congress.

Smartphone photos taken at home by patients with psoriasis can be reliably used to assess severity of disease, according to a poster presented at the European Academy of Dermatology and Venereology virtual congress.

Joint care by a dermatologist, rheumatologist and other specialists can mitigate the “accelerated trajectory of comorbidities” that can often happen in patients with psoriatic disease, according to a presenter at ACR 2020.

Among patients with psoriatic arthritis, daily upadacitinib doses of either 15 or 30 mg improved musculoskeletal symptoms, psoriasis, physical function, pain, fatigue and radiographic progression, according to a speaker at ACR Convergence.

While the rheumatology community often finds itself behind other specialties in head-to-head trials of drugs or drug classes, new data may help clinicians in decision-making, according to a presenter at ACR 2020.

A drug comprised of a nonliving single strain commensal microbe showed signs of safe and effective treatment of mild to moderate psoriasis, according to a presentation at the European Academy of Dermatology and Venereology virtual congress.